FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003277540> ?p ?o ?g. }

• W2003277540 endingPage "533" @default.
• W2003277540 startingPage "525" @default.
• W2003277540 abstract "We examined the influence of CP 154,526, a selective antagonist of corticotropin-releasing factor (CRF)1 receptors, in the locomotor, sensitizing, discriminative stimulus and rewarding effects of cocaine, as well as on the cocaine-induced reinstatement of cocaine-seeking behavior in male Wistar rats. CP 154,526 in doses of 5, 10 and 20 mg/kg, which did not affect basal locomotor activity, dose-dependently reduced the hyperactivation evoked by cocaine. To assess the effects of CP 154,526 on the expression of cocaine sensitization, the rats were injected with either saline or cocaine (10 mg/kg) for 5 days, and were then challenged with cocaine (10 mg/kg) after pretreatment with saline or CP 154,526 on day 5 of withdrawal. The cocaine-induced hyperactivity in sensitized rats was reduced by CP 154,526 (10 and 20 mg/kg). In rats trained to discriminate cocaine (10 mg/kg) from saline, pretreatment with CP 154,526 (5–20 mg/kg) did not affect the cocaine (1.25–10 mg/kg)-induced discriminative stimulus effects. In a self-administration model, the rats were trained to self-administer cocaine (0.5 mg/kg/infusion) in the FR 5 schedule of reinforcement. Administration of CP 154,526 (10–20 mg/kg) did not alter the rewarding effects of cocaine, assessed as the number of active-lever presses and infusions; however, following a 10-day extinction phase, CP 154,526 (5–20 mg/kg) significantly decreased in a dose-dependent manner the cocaine (10 mg/kg) priming-induced reinstatement of cocaine-seeking behavior. The present study implies that CRF1 receptors control the expression of cocaine hyperactivation and sensitization as well as the cocaine-induced relapse behavior, but do not play any role in cocaine discrimination and self-administration. These findings may suggest that CRF1 receptor antagonists should be considered as possible medications in the treatment of cocaine addiction." @default.
• W2003277540 created "2016-06-24" @default.
• W2003277540 creator A5013335339 @default.
• W2003277540 creator A5042882153 @default.
• W2003277540 creator A5053149454 @default.
• W2003277540 creator A5057878334 @default.
• W2003277540 creator A5088641298 @default.
• W2003277540 date "2005-10-01" @default.
• W2003277540 modified "2023-10-10" @default.
• W2003277540 title "Effects of CP 154,526, a CRF1 receptor antagonist, on behavioral responses to cocaine in rats" @default.
• W2003277540 cites W1949947575 @default.
• W2003277540 cites W1961661934 @default.
• W2003277540 cites W1969047053 @default.
• W2003277540 cites W1980606076 @default.
• W2003277540 cites W1999099783 @default.
• W2003277540 cites W2007689138 @default.
• W2003277540 cites W2014776722 @default.
• W2003277540 cites W2025072724 @default.
• W2003277540 cites W2025294582 @default.
• W2003277540 cites W2027204021 @default.
• W2003277540 cites W2027559428 @default.
• W2003277540 cites W2028948292 @default.
• W2003277540 cites W2030074654 @default.
• W2003277540 cites W2037593319 @default.
• W2003277540 cites W2044331640 @default.
• W2003277540 cites W2044688560 @default.
• W2003277540 cites W2045263476 @default.
• W2003277540 cites W2045417336 @default.
• W2003277540 cites W2052816582 @default.
• W2003277540 cites W2054533889 @default.
• W2003277540 cites W2058413635 @default.
• W2003277540 cites W2067160513 @default.
• W2003277540 cites W2071385825 @default.
• W2003277540 cites W2075990437 @default.
• W2003277540 cites W2082876506 @default.
• W2003277540 cites W2083949372 @default.
• W2003277540 cites W2091456614 @default.
• W2003277540 cites W2091760244 @default.
• W2003277540 cites W2093757762 @default.
• W2003277540 cites W2095036452 @default.
• W2003277540 cites W2103447632 @default.
• W2003277540 cites W2106862702 @default.
• W2003277540 cites W2313868102 @default.
• W2003277540 cites W4251063968 @default.
• W2003277540 cites W4376848280 @default.
• W2003277540 doi "https://doi.org/10.1016/j.npep.2005.07.002" @default.
• W2003277540 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16139885" @default.
• W2003277540 hasPublicationYear "2005" @default.
• W2003277540 type Work @default.
• W2003277540 sameAs 2003277540 @default.
• W2003277540 citedByCount "42" @default.
• W2003277540 countsByYear W20032775402012 @default.
• W2003277540 countsByYear W20032775402013 @default.
• W2003277540 countsByYear W20032775402014 @default.
• W2003277540 countsByYear W20032775402015 @default.
• W2003277540 countsByYear W20032775402016 @default.
• W2003277540 countsByYear W20032775402017 @default.
• W2003277540 countsByYear W20032775402018 @default.
• W2003277540 countsByYear W20032775402021 @default.
• W2003277540 countsByYear W20032775402022 @default.
• W2003277540 crossrefType "journal-article" @default.
• W2003277540 hasAuthorship W2003277540A5013335339 @default.
• W2003277540 hasAuthorship W2003277540A5042882153 @default.
• W2003277540 hasAuthorship W2003277540A5053149454 @default.
• W2003277540 hasAuthorship W2003277540A5057878334 @default.
• W2003277540 hasAuthorship W2003277540A5088641298 @default.
• W2003277540 hasConcept C126322002 @default.
• W2003277540 hasConcept C134018914 @default.
• W2003277540 hasConcept C15744967 @default.
• W2003277540 hasConcept C169760540 @default.
• W2003277540 hasConcept C170493617 @default.
• W2003277540 hasConcept C185592680 @default.
• W2003277540 hasConcept C2776217527 @default.
• W2003277540 hasConcept C2776885963 @default.
• W2003277540 hasConcept C2777397205 @default.
• W2003277540 hasConcept C2778555786 @default.
• W2003277540 hasConcept C2779547902 @default.
• W2003277540 hasConcept C57022672 @default.
• W2003277540 hasConcept C71924100 @default.
• W2003277540 hasConcept C98274493 @default.
• W2003277540 hasConceptScore W2003277540C126322002 @default.
• W2003277540 hasConceptScore W2003277540C134018914 @default.
• W2003277540 hasConceptScore W2003277540C15744967 @default.
• W2003277540 hasConceptScore W2003277540C169760540 @default.
• W2003277540 hasConceptScore W2003277540C170493617 @default.
• W2003277540 hasConceptScore W2003277540C185592680 @default.
• W2003277540 hasConceptScore W2003277540C2776217527 @default.
• W2003277540 hasConceptScore W2003277540C2776885963 @default.
• W2003277540 hasConceptScore W2003277540C2777397205 @default.
• W2003277540 hasConceptScore W2003277540C2778555786 @default.
• W2003277540 hasConceptScore W2003277540C2779547902 @default.
• W2003277540 hasConceptScore W2003277540C57022672 @default.
• W2003277540 hasConceptScore W2003277540C71924100 @default.
• W2003277540 hasConceptScore W2003277540C98274493 @default.
• W2003277540 hasIssue "5" @default.
• W2003277540 hasLocation W20032775401 @default.
• W2003277540 hasLocation W20032775402 @default.
• W2003277540 hasOpenAccess W2003277540 @default.

• next